Study of Two Oral Formulations of LX4211 in Patients With Type 2 Diabetes Mellitus

Inclusion Criteria: * Adults aged 18 to 65 years of age * Males and females of non-childbearing potential * Diagnosis of type 2 diabetes mellitus for at least 6 months prior to screening * Fasting plasma glucose ≤240 mg/dL * Body mass index \<42 kg/sq m * HbA1c of 7-11% * C-peptide of ≥1.0 ng/mL * Ability to provide written informed consent Exclusion Criteria: * History of type 1 diabetes mellitus, diabetic ketoacidosis, hyperosmolar nonketonic syndrome, incontinence, or nocturia * Current use of any blood glucose-lowering agent other than metformin * Exposure to insulin, thiazide, or loop diuretics within 4 weeks prior to screening * History of HIV, Hepatitis B, or Hepatitis C * Surgery within 6 months of screening * Donation or loss of \>400 mL of blood or blood product within 8 weeks prior to start of study * Use of proteins or antibodies within 12 weeks prior to screening. (Flu shots are allowed.) * Exposure to any investigational agent or participation in an investigational trial within 30 days of the start of the study * History of drug or alcohol abuse within 12 months prior to screening.